Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

SIMPLE SUMMARY: In 2020, there were 880,000 new cases and 440,000 deaths attributed to head and neck cancer worldwide. Nivolumab was approved in 2016 in the United States, and 2017 in the European Union and Canada, for use in patients with recurrent/metastatic squamous cell carcinoma of the head and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogate, Anagha, Bennett, Bryan, Poonja, Zia, Stewart, Grant, Medina Colmenero, Ana, Szturz, Petr, Carrington, Courtney, Castro, Clara, Gemmen, Eric, Lau, Ashley, Carral Maseda, Alberto, Winquist, Eric, Arrazubi, Virginia, Hao, Desiree, Cook, Audrey, Martinez Galan, Joaquina, Ugidos, Lisardo, Fernández Garay, David, Gutierrez Abad, David, Metcalf, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377225/
https://www.ncbi.nlm.nih.gov/pubmed/37509217
http://dx.doi.org/10.3390/cancers15143552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377225/
https://www.ncbi.nlm.nih.gov/pubmed/37509217
http://dx.doi.org/10.3390/cancers15143552

Ejemplares similares